TechTalk Blog
Aspreva Pharmaceuticals Announces Leadership Transition of Founding CEO Richard Glickman

Aspreva Pharmaceuticals Board of Directors today announced initiation of a process to search for a successor for founding CEO Richard Glickman, who today advised the board of his intention to step down for personal reasons. Mr. Glickman will continue in his capacity as CEO throughout the transition process, which is expected to be completed by the end of 2007.

George Milne, lead director of Aspreva’s Board of Directors stated, “We respect Richard’s decision to step down and thank him for his tireless work over the past six years. Richard has played a crucial role in founding and developing a company with an excellent financial base, strong global clinical and regulatory capabilities, and underpinned by an exceptional management team.”

Aspreva Pharmaceuticals Reports Results for First Quarter 2007

Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), today released financial results for the first quarter ended March 31, 2007. First quarter revenues were $59.3 million with net income and earnings per fully diluted share of $36.4 million and $1.03, respectively. Unless otherwise specified, all amounts are in U.S. dollars and are reported under U.S. GAAP.

“In the first quarter, we made meaningful progress in our two clinical programs, including the milestone of last patient last dose which we reached in March for the induction phase of our lupus nephritis trial. We look forward to receiving the preliminary results of this study evaluating the use of CellCept in the treatment of this disease,” said Richard M. Glickman, Chairman and Chief Executive Officer of Aspreva.

Mr. Glickman added, “As we head into the second quarter, the strength of our balance sheet and the depth of our clinical, regulatory, and commercialization skills, leave us well-positioned for the next phase of our growth as a pharmaceutical company.”

Aspreva Announces Leadership Transition of CEO

Aspreva Pharmaceuticals Board of Directors today announced initiation of a process to search for a successor for founding CEO Richard Glickman, who today advised the board of his intention to step down for personal reasons. Mr. Glickman will continue in his capacity as CEO throughout the transition process, which is expected to be completed by the end of 2007.

George Milne, lead director of Aspreva’s Board of Directors stated, “We respect Richard’s decision to step down and thank him for his tireless work over the past six years. Richard has played a crucial role in founding and developing a company with an excellent financial base, strong global clinical and regulatory capabilities, and underpinned by an exceptional management team.”

Aspreva Reports Results for First Quarter 2007

Aspreva Pharmaceuticals Corporation (NASDAQ: ASPV; TSX: ASV), today released financial results for the first quarter ended March 31, 2007. First quarter revenues were $59.3 million with net income and earnings per fully diluted share of $36.4 million and $1.03, respectively. Unless otherwise specified, all amounts are in U.S. dollars and are reported under U.S. GAAP.

“In the first quarter, we made meaningful progress in our two clinical programs, including the milestone of last patient last dose which we reached in March for the induction phase of our lupus nephritis trial. We look forward to receiving the preliminary results of this study evaluating the use of CellCept in the treatment of this disease,” said Richard M. Glickman, Chairman and Chief Executive Officer of Aspreva.

Mr. Glickman added, “As we head into the second quarter, the strength of our balance sheet and the depth of our clinical, regulatory, and commercialization skills, leave us well-positioned for the next phase of our growth as a pharmaceutical company.”

Municipal Software Announces Annual Results for 2006

Victoria, B.C., April 30, 2007— Municipal Solutions Group, Inc. (“Municipal Solutions”) (TSX Venture: MSZ), a provider of business process automation solutions for Local Government, announced the financial results for the year ending December 31, 2006 today.  Revenue increased in 2006 to $4,204,812 from $3,545,253 in 2005, an increase of 19%; fourth quarter revenues increased by 23% over the same period in the previous year. During the year the Company secured 12 new customers with a combined contracted value of licenses and services of more than US$3.2M. The Company had a loss for the year of $2,229,824 compared to a loss of $2,802,179 in 2005 as investment in the product offerings continued.The Annual General Meeting will take place on June 6th at Vancouver Island Technology Park at 2:00pm.Iain McLean, Chief Executive Officer of Municipal Solutions, commented, “2006 was a year of progress on many fronts. Revenues increased from all sources – Licenses were up 17%, Services 23% and Maintenance grew by 14% year on year. The addition of key staff members in Finance and Development ensures that we now have an experienced team in place. The move to productized solutions in 2005 has continued and we undertook a major initiative to create a Software as a Service (‘SaaS’ or ‘On-Demand’) solution for Local Government. These changes created additional costs but the Company is now poised to take advantage of this investment. The Company ended the year with a backlog of sales of CityView PreBuilts totalling over $2.5M for delivery in 2007 and we recently added to that with the purchase of CityView by Collier County, Florida in an order valued at US$1.9M.”

Municipal Software Announces Annual Results for 2006

Victoria, B.C., April 30, 2007— Municipal Solutions Group, Inc. (“Municipal Solutions”) (TSX Venture: MSZ), a provider of business process automation solutions for Local Government, announced the financial results for the year ending December 31, 2006 today.  Revenue increased in 2006 to $4,204,812 from $3,545,253 in 2005, an increase of 19%; fourth quarter revenues increased by 23% over the same period in the previous year. During the year the Company secured 12 new customers with a combined contracted value of licenses and services of more than US$3.2M. The Company had a loss for the year of $2,229,824 compared to a loss of $2,802,179 in 2005 as investment in the product offerings continued.

The Annual General Meeting will take place on June 6th at Vancouver Island Technology Park at 2:00pm.

Iain McLean, Chief Executive Officer of Municipal Solutions, commented, “2006 was a year of progress on many fronts. Revenues increased from all sources – Licenses were up 17%, Services 23% and Maintenance grew by 14% year on year. The addition of key staff members in Finance and Development ensures that we now have an experienced team in place. The move to productized solutions in 2005 has continued and we undertook a major initiative to create a Software as a Service (‘SaaS’ or ‘On-Demand’) solution for Local Government. These changes created additional costs but the Company is now poised to take advantage of this investment. The Company ended the year with a backlog of sales of CityView PreBuilts totalling over $2.5M for delivery in 2007 and we recently added to that with the purchase of CityView by Collier County, Florida in an order valued at US$1.9M.”

About Municipal Solutions Group Inc.

Municipal Solutions Group Inc was formed in January 2002 as the public financing arm for Municipal Software Corporation.

About Municipal Software Corporation

Municipal Software Corporation (TSX-V:MSZ) provides easily installed, packaged software solutions that manage the everyday business processes of local governments. The solutions are based on 24 years of experience with a product platform that easily adapts to the changing practices of clients. Branded under the CityView name, the company provides a number of out of the box solutions automating practices in Property Information, Permits and Inspections, Planning, Code Enforcement, Licensing and Cashiering. The company recently launched web based services under the Local Government Manager ™ name (available through the Application Exchange of Salesforce.com) for jurisdictions looking for the convenience and cost effectiveness of a hosted product application. Municipal Software offers a complete range of services from training and customer support of its suite of products to custom development for unique applications.

Dr. Robert Olafson Awarded Craigdarroch Gold Medal for Career Achievement in Research

Dr. Robert Olafson has been at the forefront of protein research for more than 25 years and has earned international recognition for his work in molecular parasitology.  But his greatest legacy goes far beyond single field of study.  When he joined the University of Victoria in 1981, he could see that the future of biochemical and biomedical research lay in the analysis of protein structure and function, now known as proteomics.  Determined that the University of Victoria lead the way, he established the UVic Protein Chemistry Centre.  Under his guidance, the centre blossomed into an internationally acclaimed facility.  Today, the UVic-Genome BC Proteomics Centre, the largest of its kind in Canada is located at the University of Victoria’s Vancouver Island Technology Park, provides analytical services to academic, industrial and government laboratories around the world.

Dr. Robert Olson Awarded Craigdarroch Gold Medal

Dr. Robert Olafson has been at the forefront of protein research for more than 25 years and has earned international recognition for his work in molecular parasitology.  But his greatest legacy goes far beyond single field of study.  When he joined the University of Victoria in 1981, he could see that the future of biochemical and biomedical research lay in the analysis of protein structure and function, now known as proteomics.  Determined that the University of Victoria lead the way, he established the UVic Protein Chemistry Centre.  Under his guidance, the centre blossomed into an internationally acclaimed facility.  Today, the UVic-Genome BC Proteomics Centre, the largest of its kind in Canada is located at the University of Victoria’s Vancouver Island Technology Park, provides analytical services to academic, industrial and government laboratories around the world.

Provincial Funding to Advance New Medicines

VANCOUVER – The Province is providing $25 million to the Centre for Drug Research and Development to advance new drug therapies and medicines from the discovery stage to commercialization, Premier Gordon Campbell announced today.

“Moving new medical discoveries from early development to the stage where they are available to patients can sometimes be delayed because discoveries arising out of academic research may require further testing to make them investor-ready,” said Campbell. “By supporting researchers in the early stages of their work, we will bridge the gap between primary research and the successful development of new therapies and medicines.”

The Centre for Drug Research and Development will use the funds for developing, formulating and testing new therapies and drugs, and to bridge the commercialization gap between identifying new treatments and getting them to market.

“The work done at CDRD will strengthen our growing biotech sector and will generate significant homegrown scientific successes,” said Advanced Education Minister Murray Coell. “We know that research, innovation and technology provide a long-term contribution to a strong and vibrant economy, a sustainable environment, and safe, healthy communities.

CDRD is a non-profit organization that was founded by academic and industry leaders to assist these new discoveries through the early stages of innovation to commercialization and viable companies. Based at UBC, CDRD’s facilities will have state-of-the-art equipment and will serve researchers and trainees at universities and associated institutions across B.C.

“This announcement clearly demonstrates the provincial government’s commitment to fostering and accelerating the drug development process in the province and growing B.C.’s biotech sector,” said Natalie Dakers, CDRD CEO. “This funding gives CDRD the green light to act on its plans to bridge the gap between research and the successful development of new medicines.”

Since 2001, British Columbia has invested over $1.5 billion in research and leveraged more than $900 million in added research funding from other sources. British Columbia is home to more than 90 biotech companies, making it the seventh-largest cluster in North America. B.C.-based biotech companies now employ over 2,600 workers.

Vigil Health Books Record Sales

April 16, 2007 (Victoria) – Vigil Health Solutions Inc. (“Vigil”) announces recent sales orders for nine Vigil systems for an aggregate value of approximately $700,000. Orders were received from two new corporate accounts, the addition of new facilities from three existing corporate accounts, and four new customers. These systems are expected to be commissioned during the current fiscal year.

“We are very encouraged to see the growing success of our sales program and validation of our product and service offering,” commented Troy Griffiths, President “and will continue to implement strategic initiatives to broaden our capture of the growing seniors healthcare market.”

About Vigil Health Solutions Inc. Vigil offers a proprietary technology platform combining software and hardware to provide comprehensive solutions to the expanding aged care market. Vigil has established a growing presence in North America and an international reputation for being on the leading edge of systems design and integration. The Vigil Integrated Care Management System™ (Vigil® System) includes the award-winning Vigil Dementia System, a nurse call system, bed monitoring, resident check in, and the latest development the Vigil Wireless call system. The first to supply dementia specific care technology, Vigil facilitates the highest standard of care for cognitive residents while helping dementia residents enjoy a higher quality of life and greater dignity.